Net sales rose 11% year-over-year in Q3 2024, with MRR up 38% and a major new healthcare client signed. Cash position declined, but a MSEK 17.5 rights issue post-quarter bolstered liquidity. Profitability targeted for 2025.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.